Fig. 4

Selumetinib in combination with anti-CTLA-4 alters the composition of innate cells within tumors. On day 8 after initiation of anti-CTLA-4, selumetinib or combination treatment, cells were isolated from tumors and analysed by flow cytometry to identify and characterise myeloid cells and plasmacytoid DCs (pDC). a Gating strategy used to identify CD11b⁺Ly6G⁺Ly6C^Int (I), CD11b⁺Ly6G⁻Ly6C⁺MHCII^lo/− (II), CD11b⁺Ly6G⁻Ly6C⁺MHCII⁺ (III), CD11b⁺Ly6G⁻Ly6C⁻MHCII^lo/− (IV), CD11b⁺Ly6G⁻Ly6C⁻MHCII⁺ (V) cells and CD11b⁻B220⁺PDCA1⁺ pDCs. Phenotypic analysis of CD11c, PD-L1 and CD86 expression on cells are shown as histograms with matched isotype staining (black line) and target antigen staining (grey filled). b Frequencies of myeloid cells (I-V) and pDCs (VI) out of total CD45⁺ cells. Plotted are mean ± SD. Each group contained 8 mice. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001